Editor's note: Recently, Suzhou Dianma Biological Technology Co., Ltd. (referred to as "Dianma Bio") announced that it has received angel round financing of more than 10 million yuan. This round is jointly invested by Guoqian Fund, Huatai Zijin and ETP Fund. Construction of the RECmAb recombinant monoclonal antibody technology platform and research and development of tumor immune target projects.
Dima Biology is a Sino-foreign joint venture with headquarters in Suzhou, Jiangsu and R & D base in Wuhan, Hubei. It is a recombinant monoclonal antibody R & D company focusing on tumor immune products and services. The company has the original RECmAb digital monoclonal antibody technology, which can obtain a variety of high-quality monoclonal antibodies. The company's research and development team has many years of monoclonal antibody development experience and has been widely recognized in the industry. The company is committed to the development and production of monoclonal antibodies against tumor immune targets, providing multi-faceted solutions for scientific research, clinical diagnosis and drug development worldwide. The company's corporate culture is integrity, pragmatism, innovation, and focus. Its mission is to apply advanced biotechnology to provide new and effective solutions for cancer diagnosis and treatment.
Chairman of the Association of Biotechnology: Dr. Ma Donghui
Dr. Ma Donghui, Chairman of the Association of Biocodes, said that we are very honored to receive the recognition of investors for the RECmAb recombinant monoclonal antibody innovation R & D platform and the company ’s development potential. Although it has only been a few months since its establishment, the company has grown rapidly. The original intention of the establishment of Dima Biology is to use innovative monoclonal antibody development technology to provide new solutions for the pathological diagnosis and treatment of cancer. This successful financing will greatly accelerate the company's research and development process and new product development capabilities. The Biocode team continues to use a rigorous scientific attitude to help tumor immunotherapy!
Chairman of Guoqian Venture Capital: Dr. Zhang Xu
Dr. Zhang Xu, Chairman of Guoqian Venture Capital, said that Dr. Ma Donghui and his team have accumulated many years of resources in the monoclonal antibody market at home and abroad, and have rich experience in the entire industry chain of the industry. At present, China's market for pharmaceutical antibodies and in vitro diagnostic reagents is developing rapidly. With the rise of new tumor therapies, many innovative high-value products have the opportunity to become market explosives. With the unique advantages of its unique technology platform in screening efficiency, cost, platform scalability, and quality stability, Delta Biotechnology is expected to quickly develop the clinical pathology rabbit monoclonal antibody product development, production and sales, and at the same time promote the targeting of corporate users Antibody customization service. Dianmao will have a synergistic effect with other high-tech projects located in Su Gaoxin.
General Manager of Huatai Zijin: Cao Qun
Cao Qun, general manager of Huatai Zijin, said that the unique RECmAb technology platform of Sigma Biotechnology has obvious advantages in the field of diagnosis and treatment. Hundreds of clones can be obtained in a single immunization, and therapeutic and diagnostic antibodies are screened simultaneously. The company's founding team has successfully produced several rabbit recombinant monoclonal antibodies using the platform. Delta Biotech has signed cooperation development agreements with CART R & D companies such as Porida and Beiheng Biology, and the quality and efficiency of antibody research and development have been recognized by the industry. In the future, Sigma Biology has broad development space in the fields of pathological diagnosis and tumor immunotherapy.
Founder of ETP Fund: He Weiwu, Ph.D.
Dr. He Weiwu, founder of the ETP Fund, said that tumor immunotherapy is the future of the future. In the process of tumor immunotherapy and diagnosis, there is a core element: high-quality antibodies. Under the leadership of Dr. Ma Donghui, Sigma Biotech has independently developed an efficient recombinant monoclonal antibody preparation platform and focused on antibody development in the field of tumor diagnosis and treatment. We are very optimistic about the team and technology led by Dr. Ma.
Guoqian Venture Capital Management (Suzhou) Co., Ltd.
Based on the business philosophy of "achieving the dreams of others", Guoqian Venture Capital seeks high-quality investment targets in the process of talent project introduction, innovation and entrepreneurship project evaluation, and transformation of scientific and technological achievements by experts of the National Thousand Talents Program. Resources, providing professional guidance and resource integration in technology, industry, policy, clinical, industrialization, etc. At the same time, through the introduction of talent projects and services, entrepreneurship project innovation incubation and acceleration, holding high-end industrial forums, industrial investment and integration, etc. Thousand-featured innovative technology investment and industrial integration platform. Guoqian Venture Capital has so far invested in Aishi Medical (Ophthalmology AI), Ruiqian Medical (Pathology AI), Xinqing Medical (in vitro artificial heart), Spectrum Life (mass spectrometry detection), Huanuo Biological (hemostatic material), Qing Spectrum Technology (small-scale mass spectrometry), Guoke Junhao (POCT) and many other start-up high-quality enterprises. At the same time, Guoqian Venture Capital and its parent company Guoqian Medical strive to build a medical device in China through 8-10 years through the introduction and service of talent projects, innovation incubation and acceleration of entrepreneurial projects, industrial investment and integration, etc. Industrial clusters and ecosystems have become one of the main promoters of the domestic medical device industry.